Parnell Pharmaceuticals Holdings Ltd. reported unaudited consolidated earnings results for the six months ended June 30, 2018. For the six months, the company reported Total Company sales of AUD 13.5 million comprising growth of 32% over the same period in 2017. EBITDAOI improved AUD 4.0 million to AUD 3.8 million for the six months ended 30 June 2018 over a AUD 0.2 million loss for the same period in 2017 while NPAT was AUD 2.1 million positive in 2018 compared to a loss of AUD 5.5 million in 2017.

The company now update 2018 full year revenue guidance to the range of AUD 26.0 to AUD 27.0 million and an EBITDAOI range of AUD 5.5 to AUD 6.5 million. This updated guidance replaces previous 2018 guidance, namely, revenue of AUD 25.0 to AUD 26.0 million and EBITDAOI of AUD 5.0 to AUD 6.0 million.